Management of microvascular angina pectoris

American Journal of Cardiovascular Drugs

Volumn 14, Issue 1, 2014, Pages 31-40

  Lanza, Gaetano A ^a   Parrinello, Rossella ^a   Figliozzi, Stefano ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; IVABRADINE; NICORANDIL; NITRATE; RANOLAZINE; TRIMETAZIDINE; XANTHINE DERIVATIVE;

COUNTERPULSATION; ENHANCED EXTERNAL COUNTERPULSATION; HUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPINAL CORD STIMULATION; SYNDROME X;

CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; EXERCISE TEST; FEMALE; HUMANS; MICROVASCULAR ANGINA; PERIMENOPAUSE; PROGNOSIS;

EID: 84893541509     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0052-1     Document Type: Review

References (83)

1. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010;121:2317-25.
2. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830-40.
3. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;363:498.
4. Di Franco A, Milo M, Laurito M, Nerla R, Lanza GA. Comparisons of clinical and angina characteristics between patients with cardiac syndrome X and patients with coronary artery disease. It J Practice Cardiol. 2012;1:15 - 21. (http://www.ancecardio.it).
5. Russo G, Di Franco A, Lamendola P, et al. Lack of effect of nitrates on exercise stress test results in patients with microvascular angina. Cardiovasc Drugs Ther. 2013;27:229-34.
6. Picano E, Lattanzi F, Masini M, Distante A, L'Abbate A. Usefulness of a high-dose dipyridamole-echocardiography test for diagnosis of syndrome X. Am J Cardiol. 1987;60:508-12.
7. Maseri A, Crea F, Kaski JC, Crake T. Mechanisms of angina pectoris in syndrome X. J Am Coll Cardiol. 1991;17:499-506.
8. Lanza GA, Camici PG, Galiuto L, et al. Methods to investigate coronary microvascular function in clinical practice. J Cardiovasc Med (Hagerstown). 2013;14:1-18.
9. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. J Cardiovasc Comput Tomogr. 2010;4:407.e1-33.
10. Opherk D, Zebe H, Weihe E, et al. Reduced coronary dilatory capacity and ultrastructural changes of the myocardium in patients with angina pectoris but normal coronary arteriograms. Circulation. 1981;63:817-25.
11. Chauhan A, Mullins PA, Taylor G, Petch MC, Schofield PM. Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms. Eur Heart J. 1997;18:60-8.
12. Sestito A, Lanza GA, Di Monaco A, et al. Relation between cardiovascular risk factors and coronary microvascular dysfunction in cardiac syndrome X. J Cardiovasc Med (Hagerstown). 2011;12:322-7.
13. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;328:1659-64.
14. Motz W, Vogt M, Rabenau O, Scheler S, Lückhoff A, Strauer BE. Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. Am J Cardiol. 1991;68:996-1003.
15. Chauhan A, Mullins PA, Taylor G, Petch MC, Schofield PM. Effect of hyperventilation and mental stress on coronary blood flow in syndrome X. Br Heart J. 1993;69:516-24.
16. Ong P, Athanasiadis A, Mahrholdt H, Borgulya G, Sechtem U, Kaski JC. Increased coronary vasoconstrictor response to acetylcholine in women with chest pain and normal coronary arteriograms (cardiac syndrome X). Clin Res Cardiol Clin Res Cardiol. 2012;101:673-81.
17. Lanza GA, Lüscher TF, Pasceri V, et al. Effects of atrial pacing on arterial and coronary sinus endothelin-1 levels in syndrome X. Source Am J Cardiol. 1999;84:1187-91.
18. Lanza GA, Giordano A, Pristipino C, et al. Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by [123I] metaiodobenzylguanidine myocardial scintigraphy. Circulation. 1997;96:821-6.
19. Dean JD, Jones CJ, Hutchison SJ, Peters JR, Henderson AH. Hyperinsulinaemia and microvascular angina ("syndrome X"). Lancet. 1991;337:456-7.
20. Lanza GA, Sestito A, Cammarota G, et al. Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am J Cardiol. 2004;94:40-4.
21. Rosano GM, Collins P, Kaski JC, Lindsay DC, Sarrel PM, Poole-Wilson PA. Syndrome X in women is associated with oestrogen deficiency. Eur Heart J. 1995;16:610-4.
22. Cannon RO 3rd, Quyyumi AA, Schenke WH, et al. Abnormal cardiac sensitivity in patients with chest pain and normal coronary arteries. J Am Coll Cardiol. 1990;16:1359-66.
23. Pasceri V, Lanza GA, Buffon A, Montenero AS, Crea F, Maseri A. Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. J Am Coll Cardiol. 1998;31:62-6.
24. Kaski JC, Rosano GMC, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA. Cardiac syndrome X: clinical characteristics and left ventricular function: long-term follow-up study. J Am Coll Cardiol. 1995;25:807-14.
25. Lamendola P, Lanza GA, Spinelli A, et al. Long-term prognosis of patients with cardiac syndrome X. Int J Cardiol. 2010;15(140):197-9.
26. Al Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-54.
27. Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55:2825-32.
28. Fragasso G, Chierchia SL, Pizzetti G, et al. Impaired left ventricular filling dynamics in patients with angina and angiographically normal coronary arteries: effect of beta adrenergic blockade. Heart. 1997;77:32-9.
29. Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol. 1999;84:854-6.
30. Leonardo F, Fragasso G, Rossetti E, et al. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance. Cardiologia. 1999;44:1065-9.
31. Romeo F, Gaspardone A, Ciavolella M, Gioffrè P, Reale A. Verapamil versus acebutolol for syndrome X. Am J Cardiol. 1988;62:312-3.
32. Ferrini D, Bugiardini R, Galvani M, et al. Opposing effects of propranolol and diltiazem on the angina threshold during an exercise test in patients with syndrome X. G Italian Cardiol. 1986;16:224-31.
33. Lindqvist M, Kahan T, Melcher A, Ekholm M, Hjemdahl P. Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. J Hypertens. 2007;25:169-75.
34. Cannon RO, Watson RM, Rosing DR, Epstein SE. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve. Am J Cardiol. 1985;56:242-6.
35. Ozçelik F, Altun A, Ozbay G. Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X. Clin Cardiol. 1999;22:361-5.
36. Li L, Gu Y, Liu T, et al. A randomized, single-center double-blinded trial on the effects of diltiazem sustained-release capsules in patients with coronary slow flow phenomenon at 6-month follow-up. PLoS One. 2012;7:e38851.
37. Montorsi P, Cozzi S, Loaldi A, et al. Acute coronary vasomotor effects of nifedipine and therapeutic correlates in syndrome X. Am J Cardiol. 1990;66:302-7.
38. Bugiardini R, Borghi A, Biagetti L, Puddu P. Comparison of verapamil versus propranolol therapy in syndrome X. Am J Cardiol. 1989;63:286-90.
39. Sütsch G, Oechslin E, Mayer I, Hess OM. Effect of diltiazem on coronary flow reserve in patients with microvascular angina. Int J Cardiol. 1995;52:135-43.
40. Harrison DG, Bates JN. The nitrovasodilators: new ideas about old drugs. Circulation. 1993;87:1461-7.
41. Lamendola P, Nerla R, Pitocco D, et al. Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus. Atherosclerosis. 2013;226:157-60.
42. Keating GM. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs. 2008;68:2483-503.
43. Villano A, Di Franco A, Nerla R, et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013;1(112):8-13.
44. Mehta PK, Goykhman P, Thomson LE, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011;4:514-22.
45. Borer JS, Fox K, Jaillon P, Lerebours G, for the Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina. A randomized, double blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817-23.
46. Minamino T, Kitakaze M, Morioka T, et al. Bidirectional effects of aminophylline on myocardial ischemia. Circulation. 1995;92:1254-60.
47. Crea F, Pupita G, Galassi AR, et al. Role of adenosine in pathogenesis of anginal pain. Circulation. 1990;81:164-72.
48. Emdin M, Picano E, Lattanzi F, L'Abbate A. Improved exercise capacity with acute aminophylline administration in patients with syndrome X. J Am Coll Cardiol. 1989;14:1450-3.
49. Lanza GA, Gaspardone A, Pasceri V, et al. Effects of bamiphylline on exercise testing in patients with syndrome X. G Italian Cardiol. 1997;27:50-4.
50. Radice M, Giudici V, Pusineri E, et al. Different effects of acute administration of aminophylline and nitroglycerin on exercise capacity in patients with syndrome X. Am J Cardiol. 1996;78:88-90.
51. Yoshio H, Shimizu M, Kita Y, et al. Effects of short-term aminophylline administration on cardiac functional reserve in patients with syndrome X. J Am Coll Cardiol. 1995;25:147-51.
52. Elliott PM, Krzyzowska-Dickinson K, Calvino R, Hann C, Kaski JC. Effect of oral aminophylline in patients with angina and normal coronary arteriograms (syndrome X). Heart. 1997;77:523-6.
53. Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac syndrome X: role of superoxide dismutase activity. Circulation. 2004;109:53-8.
54. Pauly DF, Johnson BD, Anderson RD. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011;162:678-84.
55. Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol. 1994;23:652-7.
56. Nalbantgil I, Onder R, Altintig A, et al. Therapeutic benefits of cilazapril in patients with syndrome X. Cardiology. 1998;89:130-3.
57. Chen JW, Hsu NW, Wu TC, et al. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002;90:974-82.
58. Camici P, Marracini P, Gistri R, et al. Adrenergically mediated coronary vasoconstriction in patients with syndrome X. Cardiovasc Drugs Ther. 1994;8:221-6.
59. Rosen SD, Lorenzoni R, Kaski JC, Foale RA, Camici PG. Effect of alpha1-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X. J Cardiovasc Pharmacol. 1999;34:554-60.
60. Galassi AR, Kaski JC, Pupita G, Vejar M, Crea F, Maseri A. Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X. Am J Cardiol. 1989;64:264-9.
61. Chen JW, Lee WL, Hsu NW, et al. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Am J Cardiol. 1997;80:32-8.
62. Yamabe H, Namura H, Yano T, et al. Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms. Cardiovasc Drugs Ther. 1995;9:755-61.
63. Nalbantgil S, Altinti A, Yilmaz H, Nalbantgil II, Önder R. The effect of trimetazidine in the treatment of microvascular angina. Int J Angiol. 1999;8:40-3.
64. Fábián E, Varga A, Picano E, Vajo Z, Rónaszé ki A, Csanády M. Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol. 2004;94:652-5.
65. Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH, Soydan I. Benefits of statin treatment in cardiac syndrome-X. Eur Heart J. 2003;24:1999-2005.
66. Collins P. Role of endothelial dysfunction and oestrogens in syndrome X. Coron Artery Dis. 1992;3:593-8.
67. Rosano GMC, Peters NS, Lefroy D, et al. Symptomatic response to 17b-estradiol in women with syndrome X. J Am Coll Cardiol. 1996;28:1500-5.
68. Albertsson PA, Emanuelsson H, Milsom I. Beneficial effect of treatment with transdermal estradiol-17-beta on exercise-induced angina and ST segment depression in syndrome X. Int J Cardiol. 1996;54:13-20.
69. Jhund PS, Dawson N, Davie AP, et al. Attenuation of endothelin-1 induced vasoconstriction by 17beta estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001;37:1367-73.
70. Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-12.
71. Cannon RO 3rd, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;330:1411-7.
72. Cox ID, Hann CM, Kaski JC. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J. 1998;19:250-4.
73. Norrsell H, Eliasson T, Mannheimer C, et al. Effects of pacing-induced myocardial stress and spinal cord stimulation on whole body and cardiac norepinephrine spillover. Eur Heart J. 1997;18:1890-6.
74. Eliasson T, Albertsson P, Hårdhammar P, Emanuelsson H, Augustinsson LE, Mannheimer C. Spinal cord stimulation in angina pectoris with normal coronary arteriograms. Coron Artery Dis. 1993;4:819-27.
75. Lanza GA, Sestito A, Sandric S, et al. Spinal cord stimulation in patients with refractory anginal pain and normal coronary arteries. Italian Heart J. 2001;2:25-30.
76. Lanza GA, Sestito A, Sgueglia GA, et al. Effect of spinal cord stimulation on spontaneous and stress-induced angina and 'ischemia-like' ST-segment depression in patients with cardiac syndrome X. Eur Heart J. 2005;26:983-9.
77. Sgueglia GA, Sestito A, Spinelli A, et al. Long-term follow-up of patients with cardiac syndrome X treated by spinal cord stimulation. Heart. 2007;93:591-7.
78. Kitsou V, Xanthos T, Roberts R, Karlis GM, Padadimitriou L. Enhanced external counterpulsation: mechanisms of action and clinical applications. Acta Cardiol. 2010;65:239-47.
79. Kronhaus KD, Lawson WE. Enhanced external counterpulsation is an effective treatment for Syndrome X. Int J Cardiol. 2009;135:256-7.
80. Lanza GA. Alternative treatments for angina. Heart. 2007;93:544-6.
81. Asbury EA, Slattery C, Grant A, Evans L, Barbir M, Collins P. Cardiac rehabilitation for the treatment of women with chest pain and normal coronary arteries. Menopause. 2008;15:454-60.
82. Bass C, Wade C. Chest pain with normal coronary arteries: a comparative study of psychiatric and social morbidity. Psychol Med. 1984;14:51-61.
83. Potts SG, Lewin R, Fox KAA, Johnstone EC, Cay EL. Group psychological treatment for chest pain with normal coronary arteries: a controlled trial. QJM. 1999;92:81-6.